Hematologic Malignancy
Classic Hodgkin Lymphoma
CI-CAN-00002375CHLExplore in graph →
Hematologic41 active trials3 approved drugs
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002375CHLExplore in graph →
Clinical trials
114 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02164500 | JAK-inhibition in Recurrent Classical Hodgkin Lymphoma(JeRiCHO) | completed | Phase 2 | 12 | University of CologneOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00654732 | Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma | completed | Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT03471351 | Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL | terminated | Phase 1 | 2 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Dec 27, 2019 | clinicaltrials |
| NCT03527628 | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy((Optimist)) | unknown | Phase 2 | 220 | King Abdullah International Medical Research CenterOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02243436 | Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 67 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Apr 24, 2019 | clinicaltrials |
| NCT03205891 | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 17, 2018 | clinicaltrials |
| NCT01460940 | A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00025259 | Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease | completed | Phase 3 | 1,734 | Children's Oncology GroupNETWORK | 7 | Apr 12, 2017 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT02808520 | Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma | unknown | — | 700 | Martin-Luther-Universität Halle-WittenbergOTHER | 0 | Jun 21, 2016 | clinicaltrials |
| NCT00082966 | Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00337194 | SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00132028 | Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00305149 | Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma | completed | N/A | 130 | Rambam Health Care CampusOTHER | 1 | Mar 21, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Apr 6, 2020source: clinicaltrials